Dr. Amancio Carnero Appointed Associate Editor of Cancers
We are pleased to announce that Dr. Amancio Carnero has been appointed Associate Editor of Cancers (ISSN: 2072-6694). With an extensive background in scientific research and publishing, he will bring a wealth of knowledge and expertise to this role.
|
|
Name: Dr. Amancio Carnero |
After graduating in biology from the Universidad de Granada (Spain), Dr. Amancio Carnero began his scientific career in the Genetics Department at the same University where he spent two years as an undergraduate student. He then moved to the Instituto de Investigaciones Biomédicas, CSIC, Madrid, and carried out his Ph.D. studies at the Department of Molecular Biology at the Universidad Autónoma de Madrid. Dr. Amancio Carnero worked on the signal transduction mechanisms induced by Ras oncogenes. Upon completing his Ph.D. in 1994, he was appointed as an Associate Professor at the Department of Biochemistry, Universidad Autónoma de Madrid, from where he moved in January 1996 to the Cold Spring Harbor Laboratory, New York, USA. Then, Dr. Carnero returned to Europe as a Senior Research Fellow at the Institute of Child Health and Great Ormond Street Hospital, University College London (UCL), UK, where he worked to improve methods for identifying new molecular targets based on functional screenings (either by gain- or loss-of-function). His research interests focused on the cell cycle, cellular senescense, and cellular immortalization. He then spent another two years in London at the Wolfson Institute for Biomedical Research (UCL) as a Senior Lecturer before returning to Spain in 2001 to assume his current position as Head of the CNIO’s Assay Development Section in the Experimental Therapeutics Programme. For 9 years, he worked at the CNIO developing the preclinical platform to identify new antitumor therapies. At the end of 2009, Amancio moved to the Institut of Biomedicine of Seville, where he followed his work in the identification and characterization of genes with therapeutic relevance in cancer, establishing causality during tumor initiation and progression, as well as the validation of new therapeutic targets.
The following is a short Q&A with Dr. Amancio Carnero, who shared his vision for the journal with us, as well as his views of the research area and open access publishing:
1. What appealed to you about the journal that made you want to take the role of its Associate Editor?MDPI is a very appealing scientific universe, where there is much more than just publications. It is very important to contribute to many areas of scientific development, not just to focus on publishing scientific works. As Associate Editor, I will have the opportunity to shape discussions, foster innovation, and support the advancement of new therapeutic approaches. My expertise could be valuable in driving forward our understanding of this complex disease and helping to consolidate emerging areas of research.
2. What is your plan and vision for the journal?My vision for the journal is clear. Focusing on consolidating the quality of existing work while actively advancing new research lines in cancer is a crucial approach. Ensuring that the journal reflects the latest developments in the field will keep it relevant and valuable to the scientific community. In addition to maintaining high standards, it might also be beneficial to foster collaborations with researchers and institutions to promote innovative studies. Engaging with the community through Special Issues or themed collections could also highlight emerging trends and encourage interdisciplinary research.
3. Which research topics do you think will be of particular interest to the research community in the coming years?There are some exciting and timely research topics that are likely to gain attention in the coming years. Tumor evolution and biomarkers are crucial for improving personalized medicine, while the use of AI in analyzing large datasets can significantly enhance our understanding of cancer dynamics. Exploring the interactions between the tumor microenvironment and external factors like aging and infections will likely yield important insights into treatment responses. Emphasizing interdisciplinary approaches can also foster innovative research that bridges gaps between different fields.
4. What do you think of the development of open access in the publishing field?Open access is essential for promoting transparency and collaboration in scientific research. By making findings readily available, researchers can build on each other’s work more effectively, accelerating discovery and innovation. It also democratizes knowledge, allowing scientists and interested individuals from various backgrounds to access valuable information without barriers. Supporting open access can enhance the journal’s reach and impact, fostering a more inclusive scientific community.
5. In your opinion, what can authors expect when they submit to Cancers?Authors can expect a supportive and rigorous submission process when submitting to Cancers. A fair review process is crucial for ensuring that all submissions are evaluated based on their scientific merit, which fosters trust and integrity in the journal. A quick turnaround time for publication is also increasingly important in the fast-paced field of cancer research, as the timely dissemination of findings can impact ongoing studies and clinical practices. Providing constructive feedback from reviewers and editors can significantly enhance the quality of manuscripts, helping authors refine their work before publication. In addition to these expectations, it might be beneficial to create a clear and transparent communication channel throughout the review process, ensuring that authors feel informed and supported.
We warmly welcome our new Associate Editor-in-Chief, Dr. Amancio Carnero, and wish the journal every success in the future.